Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

Launched by DUNES EYE CONSULTANTS · Aug 4, 2024

Keywords

ClinConnect Summary

Prospective, non-randomized, interventional study. Subjects with bilateral use of a topical immunomodulator drop and a history of dry eye disease were recruited to participate. All subjects underwent a vectored thermal pulsation treatment (LipiFlow). Patients were seen at baseline in a visit immediately prior to treatment and at months 1 and 3 following treatment. Data collected included tear osmolarity, tear break up time (TBUT), tear meniscus height (TMH), meibomian gland function and patient-reported symptoms using the ocular surface disease index (OSDI) questionnaire. Following the 3-mo...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • No prior history of meibomian gland treatment procedures LipiFlow, TearCare, or I-Lux
• • lifitegrast or cyclosporine eye drops daily for a period of at least one year but not exceeding five years
• • Meibograpy documneted retention of at least 50% of meibomian glands.
• Exclusion Criteria:
• • evidence of meibomian gland dropout exceeding 50%
• • ocular rosacea,
• • ocular surgery within the preceding three months
• • prior in-office thermal meibomian gland treatment
• • ocular trauma within preceding three months
• • ocular herpetic infection
• • chronic or recurrent inflammation
• • eyelid abnormalities affecting lid function ocular surface abnormalities compromising corneal integrity (eg, epithelial basement membrane dystrophy, corneal burn)
• • pregnant